๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Intermediate end point markers in chemoprevention trials of lung cancer

โœ Scribed by Lee, Jin S.; Kurie, Jonathan M.; Mao, Li; Morice, Rudolfo C.; Ro, Jae Y.; Lippman, Scott M.; Walter, Reuben Lotan; Hittelman, N.; Hong, Waun K.

Book ID
118575244
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
162 KB
Volume
18
Category
Article
ISSN
0169-5002

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Statistical validation of intermediate m
Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials
โœ Laurence S. Freedman; Arthur Schatzkin; Mark H. Schiffman ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 510 KB

Using an intermediate marker of precancer as an endpoint for evaluating agents that may prevent cancer involves a presumption that the modification of the marker will be accompanied by a modification of cancer incidence. This presumption can hold only if the marker is on or very closely linked to a

Assessment of DNA flow cytometry as a su
Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial
โœ Silvia Bruno; Rosalba Torrisi; Massimo Costantini; Laura Baglietto; Vincenzo Fon ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 108 KB ๐Ÿ‘ 2 views

Although conventional cytology represents the most widely performed cytometric analysis of bladder cancer cells, DNA flow cytometry has, over the past decade, been increasingly used to evaluate cell proliferation and DNA ploidy in cells from bladder washings. We have investigated whether DNA flow cy